Filing Flows › Comparisons › ATNM vs KPTI
Actinium Pharmaceuticals vs Karyopharm Therapeutics: ATNM and KPTI compared
Actinium Pharmaceuticals is the larger company: $35.0M of revenue in its latest quarter (Q2 2026) against $33.4M for Karyopharm Therapeutics (Q2 2026). Actinium Pharmaceuticals is more profitable, with an operating margin of 78.8% against -67.4%.
Where the money goes: ATNM and KPTI
Actinium Pharmaceuticals (ATNM) · Q2 2026
Actinium Pharmaceuticals, Q2 2026: revenue $35.0M, operating margin 78.8%, net earnings $27.9M, operating cash flow −$5.2M. The chart follows the revenue to costs, profit and cash.
Karyopharm Therapeutics (KPTI) · Q2 2026
Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%, net loss $67.0M, operating cash flow −$24.9M. The chart follows the revenue to costs, profit and cash.
| Actinium Pharmaceuticals (ATNM) | Karyopharm Therapeutics (KPTI) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $35.0M | $33.4M |
| Revenue growth, Y/Y | — | -12% |
| Operating margin | 78.8% | -67.4% |
| Net earnings | $27.9M | −$67.0M |
| Net margin | 79.7% | -200.5% |
| Operating cash flow | −$5.2M | −$24.9M |
Where the revenue comes from
Karyopharm Therapeutics
- Product: $30.8M (92%)
- License and Other: $2.7M (8%)
Questions
Which is bigger, Actinium Pharmaceuticals or Karyopharm Therapeutics?
Actinium Pharmaceuticals is the larger company: $35.0M of revenue in its latest quarter (Q2 2026) against $33.4M for Karyopharm Therapeutics (Q2 2026).
Is Actinium Pharmaceuticals or Karyopharm Therapeutics growing faster?
Actinium Pharmaceuticals is more profitable, with an operating margin of 78.8% against -67.4%.
More: Actinium Pharmaceuticals earnings · how Actinium Pharmaceuticals makes money · Karyopharm Therapeutics earnings · how Karyopharm Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 7, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.